flotetuzumab (flz), an investigational cd123 x cd3 bispecific dart® protein-induced clustering...
Published 3 years ago • 219 plays • Length 32:44Download video MP4
Download video MP3
Similar videos
-
1:35
flotetuzumab for primary refractory and early relapsed aml
-
5:04
flotetuzumab for primary induction failure & early relapse aml
-
4:56
flotetuzumab as salvage therapy for primary induction failure and early aml
-
1:57
is the bispecific dart, flotetuzumab, effective as salvage therapy in patients with r/r aml?
-
5:52
geoffrey l. uy, md: investigating flotetuzumab in aml and mds
-
15:28
bruker multimode afm training: imaging a sample
-
55:42
how to operate afm (with live demo) | park systems webinar
-
15:36
fei themis z s/tem: align nanoprobe
-
0:41
avm visualized with fl560 fluorescence
-
10:05
fda approval of quizartinib - vanflyta
-
1:40
the promise of cd123-directed immunotherapy in aml and agents of interest
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
4:00
marco davila -17ma030t2-bispecific car-t cell constructs for acute myeloid leukemia treatment
-
9:29
biology of bpdcn: understanding cd123
-
0:41
pelvic binder atls
-
1:50
mechanisms of gilteritinib resistance in flt3-mutated aml
-
1:58
afm: aligning contact mode cantilever
-
1:40
pivekimab sunirine in combination with venetoclax and azacitidine for cd123-positive aml
-
5:41
afm: aligning laser – maximising signal on cantilever
-
13:31
treatmentfocusedclinicalreasoning
-
2:45
imgn632 plus venetoclax and/or azacitidine for patients with cd123-positive aml
-
12:57
midl 2021, d3, feng et. al., full paper